“Sizable Upside Potential”: 4 Aggressive Biotech And Life Sciences Plays Under $10
“These are four stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” says the author of today’s…
davidgoldstein
Biogen’s Good News Could Be Great News For Other Biotechs Focused On Neurodegenerative Diseases
The FDA’s approval of Biogen’s Alzheimer’s drug “has set a precedent, showing a much easier path to approval for investigative drug treatments focused on neurodegenerative…
High Short Interest Stocks Of Interest
With the current excitement surrounding heavily shorted stocks, the author of today’s article takes a look at a number of current and former penny stocks…
COVID & Non-COVID, 3 Biotech Stocks To Watch
Against a backdrop in which investors remain keen on COVID-19 vaccine stocks such as Moderna and Novavax, and in which Biogen has just received the…
The Cutting-Edge World Of Proteomics – And What Investors Need To Know
There’s a new type of revolutionary science on the horizon: proteomics. But just what is proteomics – and what do healthcare investors need to know…
3 Biotech Stocks For 45%+ Gains
A regenerative medicine company focused on developing, manufacturing and commercializing product solutions for the advanced wound care, surgical, and sports medicine markets in the U.S.…
5 Energy Stocks Under $10 For Aggressive Traders Looking For Solid Upside Potential
“With West Texas Intermediate (WTI) crude trading near the $70 a barrel level, and expected to go even higher this summer, these stocks could have…
Ridding Cancer Patients Of “Undruggable Targets” Could Be A Boon For This Biotech Stock
What makes the biotech stock featured in today’s article a buy according to an analyst who recently initiated coverage of it? The potential for its…
Analysts See More Than 60% Upside For These 4 Biotech Stocks
“Now that the global vaccination drive is in full flight, biotech companies are working on their research and development projects to advance new therapies to…
With Its “Impressive” Blood Cancer Treatment, This Small Biotech Is Rivaling Gilead And Novartis
With what are being called “impressive” results for its blood cancer treatment, the small biotech featured in today’s article is rivaling first-in-class treatments from the…